Hoonbae Jeon, M.D. Curriculum Vitae
Hoonbae Jeon, M.D.
Associate Professor of Surgery
University of Illinois at Chicago
PERSONAL INFORMATION
Office Address:Division of Transplant (MC 958), Department of Surgery
840 South Wood Street, CSB 402
Chicago, IL 60612 / Office Telephone and FAX
(312) 996 - 6771
(312) 413 - 3483
Birth Date and Place:
February 13th 1965
Seoul, Korea
Citizenship
Republic of Korea / Social Security Number:
Available upon request
Immigration status
Permanent Resident in the U.S.
Marital Status
Married to Mikyung Ahn Jeon
Two Daughters: Chongho and Chongsoo
EDUCATION
03/01/1983-02/28/ 1985 / Premedical Course, College of Natural ScienceKorea University, Seoul, Korea
03.01.1985-02.28.1990 / M.D. / College of Medicine
Korea University, Seoul, Korea
03.01.1991-02.28.1995 / Ph.D. / Graduate School
Korea University, Seoul, Korea
POSTGRADUATE TRAINING
03.01.1990-02.28.1991 / Rotating Intern / Korea University Medical Center,Korea University, Seoul, Korea
03.01.1991-02.28.1995 / Resident / General Surgery
Korea University Medical Center
Korea University, Seoul, Korea
03.01.1996-02.28.1998 / Fellow / Division of Hepatobiliary & Pancreatic Surgery
Department of Surgery
Asan Medical Center, University of Ulsan, Seoul, Korea
07.01.2000-06.30.2001 / Fellow / Abdominal Organ TransplantationRecanati/Miller Transplant Institute
Mount Sinai Medical Center, Mount Sinai School of Medicine, New York University
New York, New York
07.01.2001-06.30.2003 / Fellow / Abdominal Organ Transplantation
Albert Einstein Medical Center, Jefferson Medical College, Thomas Jefferson University
Philadelphia, Pennsylvania
BOARD CERTIFICATION
03. 1995 / Foreign Board Certified in General Surgery (No.3463)by Korean Surgical Society and Ministry of Health and Welfare, Republic of Korea
Not eligible for American Board of Surgery
10. 1997 /
ECFMG Certificate (No. 0-439-076-1)
11. 2002 / USMLE step IIILICENSURE AND CERTIFICATIONS
03.1990 - present / National Medial Licensure of Korea (No. 40402)Ministry of Health and Welfare, Republic of Korea
2000 - 2002 / New York - inactive
2001 - 2003 / Pennsylvania - inactive
06.2003 - present / ASTS Certification of Transplant Fellowship
09.2003 - present / Kentucky (No. 38247) - active
01.2009 - present / Illinois (No. 336.083973) - active
03.2010 - present / Primary liver / living donor liver transplant surgeon at University of Illinois Hospital (ILUI) registered to UNOS
HOSPITAL PREVILLEGE
12. 2009 – present Mount Sinai Medical Center
Chicago, IL
5. 2009 – present University of Illinois Hospital at Chicago
Chicago, IL
9. 2003 – 4.2009 Albert B. Chandler Medical Center, University of Kentucky
Lexington, KY
PRESENT POSITION
5. 2009 - present / Associate Professor of Surgery (Q contract) / University of Illinois at Chicago College of MedicineChicago, Illinois
5. 2009 - present / Director, Liver Transplant and hepatobiliary Surgery / University of Illinois Hospital
Chicago, Illinois
5. 2009 – present / Director, Transplant Surgery Fellowship Program / University of Illinois at Chicago College of Medicine
Chicago, Illinois
5. 2007 - present / Adjunct Professor of Surgery / Department of Surgery
Korea University College of Medicine
Seoul, Korea
PREVIOUS POSITIONS
09.22.2003- 04.30.2009 / Assistant Professor of Surgery / Department of Surgery
University of Kentucky College of Medicine, Lexington, Kentucky
09.22.2003
- 04.30.2009 / Transplant Surgeon / University of Kentucky Transplant Center
Albert B. Chandler Medical Center
Lexington, Kentucky
07.01.2001
-06.30. 2003 / Clinical Instructor / Department of Surgery
Albert Einstein Medical Center
Jefferson Medical College,
Thomas Jefferson University
Philadelphia, Pennsylvania
03.01 2000
-6.30. 2000 / Assistant Professor of Surgery / Department of Surgery
Soonchunhyang University College of Medicine
Seoul, Korea
03.01.1998
-02.28.2000 / Instructor in Surgery / Department of Surgery
Soonchunhyang University College of Medicine Seoul, Korea
03.01.1998
-06.30.2000 / Attending Hepatobiliary Surgeon / Soonchunhyang University Hospital
Seoul, Korea
03.01.1998
-06.30.2000 / Surgical Consultant / International Clinic, Soonchunhyang University Hospital, Seoul, Korea
(A primary care facility for foreign nationals in Seoul, Korea)
03.01.1995
-02.28.1996 / Clinical Instructor in Surgery / Korea University College of Medicine
Seoul, Korea
AWARD AND HONORS
12. 2008 Faculty teaching award
Department of Surgery, University of Kentucky
10. 2004 President’s choice award for poster presentation, The Liver Meeting, AASLD, Boston MA
10.1999 – 11.1999 German Academic Exchange Service Scholar
(Deutche Akademischer Austausch Dienst: DAAD)
Department of Transplantation, Goettingen University
Professor Dr. med. Burckhard Ringe
PROFESSIONAL MEMBERSHIPS
Illinois Medical Association 2009 – present
Warren H. Cole Society 2009 - present
Fellow, American College of Surgeons 2007 - present
American Association for Study of Liver Disease 2006 – present
Fellow, International College of Surgery 2004 - present
Kentucky Medical Association 2004 - 2009
Lexington Medical Society 2004 – 2009
American Society of Transplant Surgeons 2003 - present
International Liver Transplantation Society 1999 - present
Asian Society of Hepatobiliary and Pancreatic Surgery 1997 - present
Korean Society of Hepatobiliary and Pancreatic Surgery 1996 - present
Korean Surgical Society 1995 - present
Korean Medical Association 1990 - present
COMMITTEES
ACTIVE
1. University of Illinois at Chicago
12.2011 – present Hospital Throughput Committee, University of Illinois Hospital
05.2011 – present Transfusion Practice Committee, University of Illinois Hospital
08.2009 – present Resident and Award Committee, Department of Surgery
10.2009 – present QA Committee, Department of Surgery
05.2009 – present Chairperson, Liver transplantation patient review committee, University of Illinois Hospital
05.2009 – present Kidney transplantation patient review committee, University of Illinois Hospital
2. Gift Hope Organ and Tissue Donor Network
11. 2009 – present Chairperson, Donation after cardiac death task force
02. 2010 – present Chairperson, Kidney organ procurement and distribution committee
3. UNOS
07.2009 – present Liver Transplantation Review Board, Region 7
4. American Society of Transplant Surgeons
06.2008 – present Vanguard Committee
06.2008 – present Winter Symposium Planning Committee
PAST
1. Korea University College of Medicine, Seoul, Korea
3.1994 - 2.1995 Chairperson, Committee of Chief Residents
2. Soonchunhyang University College of Medicine, Seoul, Korea
8.1998 - 6.2000 Co-Chair, Hospital Nutrition Committee
9.1999 - 6.2000 Task Force for Faculty Evaluation Standard Development
11.1999 - 6.2000 Organ Transplantation Committee
3. Korean Surgical Society
11. 1996 - 10. 1998 Editorial Committee
11.1998 - 6.2000 Residency Program Review Committee
4. University of Kentucky College of Medicine, Lexington, KY
09. 2003 – 03. 2007 Transplantation Steering Committee
09. 2003 – 04. 2009 Liver Transplant Evaluation Committee
09. 2003 - 04. 2009 Pancreas Transplant Evaluation Committee
09. 2003 - 04. 2009 Kidney Transplant Evaluation Committee
02. 2008 – 04. 2009 Liver Transplant Core Group for Multidisciplinary Collaboration
03. 2008-04.2009 Task force for end-stage liver disease service
5. UNOS
09.2003 - 04.2009 Liver Transplantation Review Board, Region 11
5. International College of Surgeons
01.2008 – 01.2011 Continuous Medical Education Committee
EDITORIAL ACTIVITIES
11.1996 - 9.1998 Assistant Editor, Journal of Korean Surgical Society
10.2008 - present Abstract Reviewer, Winter Symposium, American Society of Transplant Surgeons
09. 2006 – present Peer reviewer, Liver Transplantation
07.2010 – present Peer reviewer, American Journal of Surgery
03.2011 – present Associate Editor, BMC Gastroenterology
12.2011 – present Peer Reviewer, International Journal of Gastrointestinal Cancer
01.2012 – present Peer Reviewer, Mount Sinai Journal of Medicine
RESEARCH SUPPORT
Current Projects
2008-0002 / Co-Investigator (PI: West-Thielke, Patricia) / A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients / Active / 03/03/20122008-1085 / Co-Investigator (PI: West-Thielke, Patricia) / Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation / Active / 12/16/2011
2008-1091 / Co-Investigator (PI: West-Thielke, Patricia) / A Phase 3, Open-Label, Multicenter, Prospective, Randomized Study of the Efficacy and Safety of Conversion From Prograf Capsules Twice Daily to LCP-TACRO Tablets Once Daily for the Prevention of Acute Allograft Rejection in Stable Kidney Transplant Patients / Active / 12/16/2011
2009-1213 / Co-Investigator (PI: West-Thielke, Patricia) / A Collaborative Experience Using Bortezomib for the Treatment of Antibody Mediated Rejection in Solid Organ Transplantation / Active / 03/09/2012
2010-0202 / Co-Investigator (PI: West-Thielke, Patricia) / Analysis of Risk Factors for Long Term Outcomes of Kidney and/or SPK Transplant Recipients (OPTN) / Active / 02/22/2012
2010-0702 / Co-Investigator (PI: West-Thielke, Patricia) / A Phase 1b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Single-Dose, Pharmacokinetic, Safety and Tolerability Study of ASKP1240 in de Novo Kidney Transplantation / Active / 08/31/2011
2010-1013 / Co-Investigator (PI: West-Thielke, Patricia) / The Effects of Thymoglobulin on Immune Cell Function / Active / 01/27/2012
2011-0112 / Co-Investigator (PI: West-Thielke, Patricia) / A Phase 3, Double-Blind, Double-Dummy, Multi-Center, Prospective, Randomized Study of the Efficacy and Safety of LCP-Tacro Tablets, Once Daily, Compared to Prograf Capsules, Twice Daily, in Combination with Mycophenolate Mofetil for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients / Active / 02/15/2012
Previous Projects
1. Primary Investigator “CellCept (mycophenolate mofetil) maintenance immunosuppression in liver transplant recipients with long-term follow-up posttransplantation of non-autoimmune lie r disease – A prospective, randomized, multicenter trial.”. Sponsor: Roche/Albert Einstein Medical Center. $ 37,298.74 Protocol No. CEL350, IRB 060892F1V
2. Co-Investigator (PI: Ranjan D) “A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants.” Sponsor: ViroPharma. $ 116,495, 07-0541-F6A
3. Co-Investigator (PI: Ranjan D) “A Randomized, Open- Label, Comparative Evaluation of Conversion from Calineurin Inhibitor Treatment Versus Continued Calineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy”. Sponsor: Wyeth Research. $263,193, 2002- Protocol 0468H1-316-US
4. Co-Investigator (PI: Johnston TD) “A Prospective, Randomized, Multi-Center Double-Blind Study of Early Corticosteroid Cessation vs. Long-Term Maintenance Corticosteroid Therapy with Zenapax, Prograf, and CellCept in Primary Renal Transplant Recipients.” Sponsor: Fujisawa Healthcare Incorporated Funding: $120,000 (projected) 6 subjects enrolled. Protocol Number 20-99-001.
5. Co-Investigator (PI: Johnston TD) “A 24-Month, Multicenter, Randomized, Open-Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration-Controlled Certican® in Two Doses (1.5 and 3.0 mg/day Starting Doses) with Reduced Neoral® versus 1.44 Myfortic® with Standard Dose Neoral in de novo Renal Transplant Recipients (2309)” Sponsor: Novartis $ 339,206.63, 05-0639-F1V
6. Co-Investigator (PI: Johnston TD) “A Facilitated Access Program to Provide Everolimus (RAD) for Maintenance Patients Completing Therapy in RAD Trials in Solid Organ Transplantation (2401)” Sponsor: Novartis $ 25,010, 76 07-0892-F6A
7. Co-Investigator (PI: Johnston TD) “Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (IM103-008)” Sponsor: BMS $ 253,525, 06-0436-F1V
8. Co-Investigator (PI: Johnston TD) “A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept-Based Corticosteroid-Free Regimens in Renal Transplant (IM103-034)” Sponsor: BMS $ 67,264 07-0661-F6A
9. Co-Investigator (PI: Johnston TD) “A 24-Month, Multicenter, Randomized, Open-Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration-Controlled Certican® in Two Doses (1.5 and 3.0 mg/day Starting Doses) with Reduced Neoral® versus 1.44 Myfortic® with Standard Dose Neoral in de novo Renal Transplant Recipients (2309)” Sponsor: Novartis $ 339,206.63 05-0639-F1V
10. Co-Investigator (PI: Johnston TD) “A Randomized, Open-label, Study to Compare the Safety and Efficacy of Two Different Rapamune Regimens With A Tacrolimus+ Mycopheonlate Mofetil Regimen In De Novo Renal Allograft Recipients (ORION)” Sponsor: Wyeth $ 124,308 04-0387-F2L
11. Co-Investigator (PI: Johnston TD) “A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients (316)” Sponsor: Wyeth $ 225,900 03-0054-F3R
12. Primary Investigator “A Prospective, Randomized, Open-Label, Twenty-Six Week Study of the Efficacy and Safety of Converting Liver Transplant Recipients with Tacrolimus-Associated Abnormal Glucose Metabolism to Neoral with C2 Monitoring.” . Novartis Pharmaceuticals Corporation, 2003 Funding: $75,000 Projected enrollment: 10 Site initiated: 1/30/04 Currently enrolled: 2, Closed Protocol COLO 400A US 06
13. 7/2000-6/2001 Co-Investigator. (PI: Sheiner P.) A Randomized, Open-Label Preference Study of Gengrafä Compared to Neoralâ in Stable Solid-Organ Transplant Subjects. GCO# 00-0454.Abbott Laboratories, $75,000.00
14. 7/2000-6/2001 Co-Investigator (PI:Fishbein T.) A Randomized, Comparative Trial of Prograf (Tacrolimus) in Combination with Sirolimus or Mycophenolate Mofetil after Liver Transplantation. GCO# 00-0451.Fujisawa Health Care Inc. $80,000.00.
15. 7/2000-6/2001 Co-Investigator (PI:Sheiner P.) A Prospective, Randomized, Multicenter, Open-Label, Comparative Safety and Efficacy Study of Prophylactically Administered Pegylated Interferon alfa-2a (Pegasys®) Plus Ribavirin vs. No Prophylaxis Following Liver Transplantation for Hepatitis C. National Institutes of Health. GCO # 99-1022. $352,464.00. 5 %
16. 7/2000-6/2001 Co-Investigator (PI:Sheiner P.) Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5%, Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination with Lamivudine for Patients with Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation” Gco # 99-1005.Mayo Clinic. Total Grant $6,000.00
17. 7/2000-6/2001 Co-Investigator (PI:Sheiner P.) The Pharmacokinetics and Safety of Boca HBVIg Given Intravenously to Patients Following Orthotopic Liver Transplantation for Chronic Hepatitis B. Nabi Pharmaceuticals. GCO # 99-0852.Total Grant: $57,600.00
18. 7/2000-6/2001 Co-Investigator (PI:Burrows L.)Prograf (tacrolimus) as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure. GCO# 99-0115. Fujisawa Health Care Inc. $18,000.00
19. 7/2000-2/2001 Co-Investigator (PI: Bromberg J.)Multicenter, randomized, partially-blinded study of the safety and efficacy of FTY 720 combined with corticosteroids and full or reduced-dose Neoral in de novo adult renal transplant recipients. GCO# 00-0132 Novartis Pharmaceuticals: $ 85,000.00
20. 7/2000-4/2001 Co-Investigator (PI: Emre S.) A multi-center, randomized, double-blind, parallel group, placebo-controlled dose exploratory trial evaluating the safety and effect of activated recombinant factor VIIa (rFVIIa/ NovoSevenâ) in the prevention of bleeding in subjects undergoing orthotopic liver transplantation. GCO# 00-0002.NovoNordisk Pharmaceuticals. $ 200,000.00
21. 7/2000-6/2001 Co-Investigator (PI: Bromberg J.) “A 1-Year, Multicenter, Single Arm, Open Label, Pilot Study of the Efficacy and Safety of RAD in de novo Renal Transplant Recipients At Immunological High Risk of Rejection”. GCO# 00-0181.Novartis Pharmaceuticals. $58,000.00